Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
2024年9月24日 - 9:05PM
ビジネスワイヤ(英語)
Mr. Parker has More Than 25 Years of Commercial
Leadership Experience and has Launched Multiple Rare Disease
Products
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage
biopharmaceutical company focused on rare respiratory diseases,
today announced the appointment of Braden Parker as Chief
Commercial Officer, effective immediately. Mr. Parker is a seasoned
global commercial leader with more than 25 years of experience in
the healthcare and biotech industry. Throughout his career, he has
developed and executed global commercial plans, including market
expansion activities, built high-performance teams, and launched
multiple successful rare disease products. Mr. Parker is
responsible for overseeing Savara's global commercial strategy for
molgramostim inhalation solution (molgramostim) in autoimmune
Pulmonary Alveolar Proteinosis (aPAP).
“I am happy to welcome Braden to Savara, particularly as we
approach a transformational milestone with the potential approval
and launch of molgramostim,” said Matt Pauls, Chair and CEO of
Savara. “Braden is an accomplished leader with a proven track
record of building commercial teams, leading successful rare
disease product launches and accelerating growth for companies as
they transition to the commercial stage. We are thrilled to have
him as part of our team and look forward to his contributions.”
Mr. Parker joins Savara from Orchard Therapeutics (Kyowa Kirin),
where he served as Chief Commercial Officer. In this role, he was
responsible for global commercial strategy and execution for the
company’s unique ex-vivo autologous HSC gene therapy product
portfolio, including overseeing Orchard Therapeutics' first product
launch, Libmeldy, for the treatment of metachromatic leukodystrophy
(MLD), a rare hereditary disease. Prior to joining Orchard
Therapeutics, he served as Vice President and General Manager for
the U.S. organization for PTC Therapeutics and led the company’s
first U.S. product launch in Duchenne muscular dystrophy. Earlier
in his career, Mr. Parker held commercial leadership roles at
Celgene and NPS Pharma (Shire). Mr. Parker received his M.B.A. from
New York University Stern School of Business and his B.B.A. from
the University of Notre Dame.
“I am pleased to join Savara and work with a group of talented
leaders who are deeply committed to developing and delivering
transformative therapeutics for patients suffering from rare
disease,” said Mr. Parker. “I believe molgramostim, if approved, is
uniquely positioned to make a significant impact in the treatment
of aPAP, and it is a privilege to be able to bring my experience
and knowledge to Savara to support a product with such great
potential.”
Savara plans to complete submission of a Biologics License
Application (BLA) to the U.S. Food and Drug Administration (FDA)
for molgramostim for the treatment of aPAP in the first half of
2025. If approved, molgramostim would be the first and only
treatment for aPAP in the U.S. and Europe. Molgramostim has been
granted Orphan Drug, Fast Track, and Breakthrough Therapy
designation from the FDA, Orphan Drug designation from the European
Medicines Agency and Innovative Passport and Promising Innovative
Medicine designation from the UK's Medicines and Healthcare
Products Regulatory Agency for the treatment of aPAP.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim
inhalation solution, is a granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH)
specifically developed for inhalation of a large molecule. Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
Forward-Looking Statements
Savara cautions you that statements in this press release that
are not a description of historical fact are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by
the use of words referencing future events or circumstances such as
“expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,”
among others. Such statements include, but are not limited to,
statements related to the anticipated timing of our BLA submission,
the potential impact of molgramostim on the treatment of aPAP, and
molgramostim’s potential to be the first and only approved
therapeutic for aPAP in the U.S. and Europe. Savara may not
actually achieve any of the matters referred to in such
forward-looking statements, and you should not place undue reliance
on these forward-looking statements. These forward-looking
statements are based upon Savara’s current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, the risks associated with our ability
to successfully develop, obtain regulatory approval for, and
commercialize molgramostim for aPAP; the actions and decisions of
regulatory authorities; the risks and uncertainties related to the
impact of widespread health concerns or changing economic or
geopolitical conditions; the ability to project future cash
utilization and reserves needed for contingent future liabilities
and business operations; the availability of sufficient resources
for Savara’s operations and to conduct or continue planned clinical
development programs; and the timing and ability of Savara to raise
additional capital as needed to fund continued operations. All
forward-looking statements are expressly qualified in their
entirety by these cautionary statements. For a detailed description
of our risks and uncertainties, you are encouraged to review our
documents filed with the SEC including our recent filings on Form
8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue
reliance on forward-looking statements, which speak only as of the
date on which they were made. Savara undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240924542532/en/
Savara Inc. IR & PR Anne
Erickson (anne.erickson@savarapharma.com) (512) 851-1366
Savara (NASDAQ:SVRA)
過去 株価チャート
から 9 2024 まで 10 2024
Savara (NASDAQ:SVRA)
過去 株価チャート
から 10 2023 まで 10 2024